Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Pupa, Serenella M."'
Autor:
Castagnoli L; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Corso S; Department of Oncology, University of Torino, Candiolo, Turin, Italy.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy., Franceschini A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Raimondi A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy., Bellomo SE; Department of Oncology, University of Torino, Candiolo, Turin, Italy.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy., Dugo M; Department of Medical Oncology-Breast Cancer Unit Clinical Translational and Immunotherapy Research, IRCCS Ospedale San Raffaele, Milan, Italy., Morano F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy., Prisciandaro M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy., Brich S; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Belfiore A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Vingiani A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Di Bartolomeo M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy., Pruneri G; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Giordano S; Department of Oncology, University of Torino, Candiolo, Turin, Italy.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy., Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133, Milan, Italy. filippo.pietrantonio@istitutotumori.mi.it., Pupa SM; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. serenella.pupa@istitutotumori.mi.it.
Publikováno v:
Cellular oncology (Dordrecht) [Cell Oncol (Dordr)] 2023 Jun; Vol. 46 (3), pp. 661-676. Date of Electronic Publication: 2023 Feb 08.
Autor:
De Santis F; Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology and Hematology Fondazione, IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Romero-Cordoba SL; Department of Genomic Medicine and Toxicology, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.; Biochemistry Department, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Mexico., Castagnoli L; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Volpari T; The New York Stem Cell Foundation Research Institute, New York, NY, USA., Faraci S; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Fucà G; Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology and Hematology Fondazione, IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., De Braud F; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Department of Oncology and Oncohematology, University of Milan, Milan, Italy., Pupa SM; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Di Nicola M; Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology and Hematology Fondazione, IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. massimo.dinicola@istitutotumori.mi.it.
Publikováno v:
Cellular oncology (Dordrecht) [Cell Oncol (Dordr)] 2022 Apr; Vol. 45 (2), pp. 257-274. Date of Electronic Publication: 2022 Mar 31.
Autor:
Koschorke A; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Faraci S; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Giani D; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Chiodoni C; Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Iorio E; Core Facilities, NMR and MRI Unit, Istituto Superiore di Sanità, Rome, Italy., Canese R; Core Facilities, NMR and MRI Unit, Istituto Superiore di Sanità, Rome, Italy., Colombo MP; Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Lamolinara A; Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. D'Annunzio University, Chieti-Pescara, Italy., Iezzi M; Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), G. D'Annunzio University, Chieti-Pescara, Italy., Ladomery M; Faculty of Health and Applied Sciences, University of the West of England, Coldharbour Lane, Frenchay, Bristol, BS16 1QY, UK., Vernieri C; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; IFOM, FIRC Institute of Molecular Oncology, Università degli Studi di Milano, Milan, Italy., de Braud F; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Di Nicola M; Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Castagnoli L; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pupa SM; Molecular Targeting Unit, Department of Research, AmadeoLab, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. serenella.pupa@istitutotumori.mi.it.
Publikováno v:
Cellular oncology (Dordrecht) [Cell Oncol (Dordr)] 2019 Dec; Vol. 42 (6), pp. 815-828. Date of Electronic Publication: 2019 Aug 02.